Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 10.3389/fphar.2019.00148 Pharmacology Correction Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases Cavalli Giulio 1 2 * Dinarello Charles A. 2 3 * 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy 2Department of Medicine, Radboud University Medical Center, Nijmegen, Netherlands 3Department of Medicine, University of Colorado Denver, Denver, CO, United States

Edited and reviewed by: Paolo Sfriso, University of Padova, Italy

 *Correspondence: Giulio Cavalli cavalli.giulio@gmail.com Charles A. Dinarello cdinare333@aol.com

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

 08 03 2019 2019 10 148 11 01 2019 08 02 2019 Copyright © 2019 Cavalli and Dinarello. 2019 Cavalli and Dinarello

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Anakinra Therapy for Non-cancer Inflammatory Diseases by Cavalli, G., and Dinarello, C. A. (2018). Front. Pharmacol. 9:1157. doi: 10.3389/fphar.2018.01157 interleukin 1 IL-1β IL-1α rheumatology inflammation

In the original article “Anakinra Therapy for Non-cancer Inflammatory Diseases”, we failed to provide citations for publications relevant to the discovery of IL-1Ra. The citations have now been inserted in the Introduction, Historical Background of IL-1 and IL-1Ra and should read:

“As stated in our review (Cavalli and Dinarello, 2018), in 1981 we described a circulating suppressor factor from humans during experimental endotoxemia as assayed for specific inhibition of IL-1 activity in vitro (Dinarello et al., 1981). We believe this circulating suppressor factor was the first description of IL-1Ra, and we confirmed our findings in a report published in Lancet in 1991 using a specific radioimmunoassay for IL-1Ra (Granowitz et al., 1991). However, in 1984, there was documentation from the group of Jean-Michel Dayer describing a specific inhibitor of IL-1 activity isolated from the urine of patients with monoblastic leukemia (Balavoine et al., 1984). This was an essential contribution to the history of the discovery of the antagonist. In 1985, there was another report from the Dayer laboratory “Collagenase- and PGE2-Stimulating Activity (Interleukin-1-Like) and Inhibitor in Urine from a Patient with Monocytic Leukemia”, as published in Progress in Leukocyte Biology, vol. 2 (New York, NY: Alan R. Liss, 1985 p. 429). These reports were followed by another publication in the Journal of Clinical Investigation (Balavoine et al., 1986). As stated in our Review, “the IL-1 inhibitor” isolated from the urine was shown to prevent binding of IL-1 to cells (Seckinger et al., 1987), thus providing for the first time evidence for its mechanism of action. Because of the widespread and beneficial use of anakinra (the recombinant form of the nature IL-1Ra) to treat human diseases, the contributions of Jean-Michel Dayer as well as those of William Arend are paramount.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

References Balavoine J. F. de Rochemonteix B. Williamson K. Seckinger P. Cruchaud A. Dayer J.-M. (1984). Identification of interleukin 1-like activity and inhibitor(s) in urine from a patient with acute monoblastic leukemia. Lymphokine Res. 3:23. Balavoine J. F. de Rochemonteix B. Williamson K. Seckinger P. Cruchaud A. Dayer J.M. (1986). Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78, 1120–1124. 10.1172/JCI1126693020090 Cavalli G. Dinarello C. A. (2018). Anakinra therapy for non-cancer inflammatory diseases. Front. Pharmacol. 9:157. 10.3389/fphar.2018.0115730459597 Dinarello C. A. Rosenwasser L. J. Wolff S. M. (1981). Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J. Immunol. 127, 2517–2519. 6795276 Granowitz E. V. Santos A. Poutsiaka D. Cannon J. G. Wilmore D. A. Wolff S. M. . (1991). Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 338, 1423–1424. Seckinger P. Lowenthal J. W. Williamson K. Dayer J. M. MacDonald H. R. (1987). A urine inhibitor of interleukin 1 activity that blocks ligand binding. J. Immunol. 139, 1546–1549. 2957429